Details

Autor(en) / Beteiligte

• Burgos, Leire
• Tamariz-Amador, Luis-Esteban
• Puig, Noemi
• Cedena, Maria-Teresa
• Guerrero, Camila
• Jelínek, Tomas
• Johnson, Sarah
• Milani, Paolo
• Cordon, Lourdes
• Perez, Jose J
• Lasa, Marta
• Termini, Rosalinda
• Oriol, Albert
• Hernandez, Miguel-Teodoro
• Palomera, Luis
• Martinez-Martinez, Rafael
• de la Rubia, Javier
• de Arriba, Felipe
• Rios, Rafael
• Gonzalez, Maria-Esther
• Gironella, Mercedes
• Cabañas, Valentin
• Casanova, Maria
• Krsnik, Isabel
• Perez-Montaña, Albert
• González-Calle, Verónica
• Rodriguez-Otero, Paula
• Maisnar, Vladimir
• Hajek, Roman
• Van Rhee, Fritz
• Jimenez-Zepeda, Victor
• Palladini, Giovanni
• Merlini, Giampaolo
• Orfao, Alberto
• de la Cruz, Javier
• Martinez-Lopez, Joaquin
• Lahuerta, Juan-Jose
• Rosiñol, Laura
• Blade, Joan
• Mateos, Maria-Victoria
• San-Miguel, Jesus F
• Paiva, Bruno

Titel

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

Ist Teil von

• Journal of clinical oncology, 2023-06, Vol.41 (16), p.3019-3031

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated. An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM. The clinical significance of the algorithm was tested and validated in 488 patients with smoldering MM, 3,870 patients with active MM and 211 patients with AL amyloidosis. Patients with smoldering MM with MGUS-like phenotype showed significantly lower rates of disease progression (4.5% and 0% at 2 years in two independent series). There were no statistically significant differences in time to progression between treatment versus observation in these patients. In active newly diagnosed MM, MGUS-like phenotype retained independent prognostic value in multivariate analyses of progression-free survival (PFS; hazard ratio [HR], 0.49; = .001) and overall survival (OS; HR, 0.56; = .039), together with International Staging System, lactate dehydrogenase, cytogenetic risk, transplant eligibility, and complete remission status. Transplant-eligible patients with active MM with MGUS-like phenotype showed PFS and OS rates at 5 years of 79% and 96%, respectively. In this subgroup, there were no differences in PFS and OS according to complete remission and measurable residual disease status. Application of the algorithm in two independent series of patients with AL predicted for different survival. We developed an open-access algorithm for the identification of MGUS-like patients with distinct clinical outcomes. This phenotypic classification could become part of the diagnostic workup of MM and AL amyloidosis.